Lori England Wright, MD
General Practice · Bowling Green, KYNPI 1477536829
Payments from drug & device makers
Across 157 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$480
- Novo Nordisk$292
- GSK$262
- AstraZeneca$252
- Merck$222
- Insulet Corporation$119
- plus $968 from 25 others
What the payments were for
- Food & beverage$2,595100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 32 | $480 |
| Novo Nordisk | 27 | $292 |
| GSK | 16 | $262 |
| AstraZeneca | 9 | $252 |
| Merck | 15 | $222 |
| Insulet Corporation | 3 | $119 |
| Axsome Therapeutics, Inc. | 5 | $90 |
| Pfizer | 4 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $71 |
| Sanofi-aventis U.S. LLC | 3 | $71 |
| Amarin Pharma, Inc. | 4 | $62 |
| Amgen | 4 | $60 |
| Dexcom, Inc. | 3 | $55 |
| Lilly USA, LLC | 4 | $54 |
| Phathom Pharmaceuticals, Inc. | 2 | $45 |
| Johnson & Johnson | 2 | $41 |
| Hologic Sales And Service, LLC | 2 | $35 |
| Novartis | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Boehringer Ingelheim | 1 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Biogen | 1 | $26 |
| Valeritas, Inc. | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Mylan Specialty L.p. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $15 |
| Cranial Technologies, Inc | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Bayer | 1 | $13 |
| Astellas Pharma US Inc | 1 | $11 |
How this compares
$2,595 in reported general payments places this provider in the 90th percentile of 1,155 general practice providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 209 | $188,874 |
| OzempicSemaglutide | 148 | $158,928 |
| JanuviaSitagliptin Phosphate | 86 | $83,341 |
| VraylarCariprazine Hcl | 30 | $50,021 |
| FarxigaDapagliflozin Propanediol | 64 | $48,893 |
| TrulicityDulaglutide | 47 | $47,699 |
| TradjentaLinagliptin | 67 | $46,096 |
| EliquisApixaban | 42 | $35,898 |
| Tresiba Flextouch U-100Insulin Degludec | 39 | $33,366 |
| MounjaroTirzepatide | 31 | $31,662 |
| LinzessLinaclotide | 29 | $27,249 |
| UbrelvyUbrogepant | 11 | $23,680 |
| TrintellixVortioxetine Hydrobromide | 20 | $18,133 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 32 | $16,181 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 21 | $14,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $32 | $251,151308 claims |
| Novo NordiskOzempic | $292 | $158,928148 claims |
| AbbVieVraylar, Linzess, Ubrelvy | $480 | $100,95070 claims |
| MerckJanuvia | $222 | $83,34186 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $54 | $79,36178 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $252 | $63,36585 claims |
| PfizerEliquis | $74 | $35,89842 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $33 | $18,13320 claims |
| GSKAnoro Ellipta | $262 | $11,14216 claims |
| Astellas Pharma US IncMyrbetriq | $11 | $10,50321 claims |
| NovartisEntresto | $34 | $8,73411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,155 general practice providers in Kentucky.
Other general practice in Bowling Green
- Thomas BirkenhauerBowling Green$3K
- Eric SchneebergerWarsaw$539K
- Stephen SterlitzLexington$263K
- Ryan LewisFrankfort$190K
- Jerome WellbrockCovington$173K
- William WorkmanLexington$166K
- Shana HughesRussell Springs$85K
- Pamela SteinHazard$60K
- Bryan HarrisLouisville$53K
- Bach NguyenUnion$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.